A Phase IV Study to Investigate the Safety and Efficacy of Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).
Phase of Trial: Phase IV
Latest Information Update: 13 Nov 2018
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bayer
- 22 Aug 2018 Status changed from not yet recruiting to recruiting.
- 20 Jul 2018 Planned initiation date changed from 29 Jun 2018 to 23 Jul 2018.
- 28 Jun 2018 New trial record